F8 and autoimmune hemolytic anemia: The standard treatment involves immunosuppressive agents such as PSL, CPA, and rituximab to eradicate FVIII inhibitors and hemostatic therapy using bypassing agents such as rFVIIa or aPCC, which activate the coagulation cascade independently of FVIII.1–6) Recombinant porcine factor VIIIa has recently emerged as another effective treatment option for patients with severe bleeding.1,3) However, there is currently no standardized strategy for safe perioperative hemostasis in patients with AHA undergoing surgical procedures.